Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

AJANTA PHARMA LTD. - 532331 - Board Meeting Outcome for Outcome Of Board Meeting For Approving Audited Financial Results And Proposal Of Buy Back Pursuant To Reg 33 And 30 Of SEBI (LODR)

 We hereby inform that at the Board meeting held on Thursday, 2nd May 2024, Board has inter-alia approved the following: 1. Audited (Consolidated & Standalone) Financial Results of the Company for the quarter and year ended 31st March 2024. 2. Proposal of Buy Back. PFA enclosed outcome of Board Meeting for more details.
02-05-2024
Bigul

Annual report for Ajanta Pharma Ltd. for FY-2024
02-05-2024
Bigul

AJANTA PHARMA LTD. - 532331 - Update on board meeting

 AJANTA PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/05/2024 ,inter alia, to consider and approve Pursuant to Regulation 29(1)(b) of the Listing Regulations and in continuation to our intimation dated April 22, 2024 about meeting of the Board of Directors of the Company scheduled to be held on Thursday, May 2, 2024, we hereby inform that at the said meeting, the Board will also consider a proposal for buy-back of Equity Shares of the Company and other matters incidental and necessary thereto, in accordance with the applicable provisions of the Companies Act, 2013 (including the rules and regulations framed thereunder), the Securities and Exchange Board of India (Buy-back of Securities) Regulations, 2018, as amended, and other applicable laws.
26-04-2024
Bigul

AJANTA PHARMA LTD. - 532331 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we are enclosing herewith the schedule of Earnings Conference Call to be held on 2nd May 2024, post Board meeting.
23-04-2024
Bigul

AJANTA PHARMA LTD. - 532331 - Board Meeting Intimation for Board Meeting Scheduled To Be Held On Thursday 2Nd May 2024 To Consider And Approve Audited Financial Results (Consolidated & Standalone) For The Quarter And Year Ended 31St March 2024.

 AJANTA PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/05/2024 ,inter alia, to consider and approve a. Audited Financial Results (consolidated & standalone) of the Company for the quarter and year ended 31st March 2024; and b. Audited Financial Statements (consolidated & standalone) for the year ended 31st March 2024.
22-04-2024
Bigul

AJANTA PHARMA LTD. - 532331 - Compliance With Reg. 40(10) Of The Listing Regulations - Compliance Certificate

 PFA herewith Compliance Certificate under Regulation 40(10) of the SEBI (LODR) Regulations, 2015 from a PCS for the year ended 31st March 2024.
18-04-2024
Bigul

AJANTA PHARMA LTD. - 532331 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

 Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyAJANTA PHARMA LTD. 2CIN NO.L24230MH1979PLC022059 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY A1+ 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CARE RATINGS LIMITED 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkNSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Gaurang Shah Designation: VP Legal and Company Secretary EmailId: [email protected] Name of the Chief Financial Officer: Arvind Agrawal Designation: CFO EmailId: [email protected] Date: 15/04/2024 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
15-04-2024
Bigul

AJANTA PHARMA LTD. - 532331 - Compliance Certificate - Regulation 7(3) Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015 For The Period Ended 31St March 2024.

 Compliance Certificate - Regulation 7(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for FY 2024.
15-04-2024
Bigul

AJANTA PHARMA LTD. - 532331 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 PFA intimation w.r.t issue of duplicate share certificate.
12-04-2024
Bigul

AJANTA PHARMA LTD. - 532331 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 PFA herewith certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31.03.2024 received from Link Intime Pvt Ltd, RTA of the Company.
11-04-2024
Next Page
Close

Let's Open Free Demat Account